VolitionRx (VNRX) Competitors $0.60 -0.03 (-5.18%) Closing price 09/5/2025 03:59 PM EasternExtended Trading$0.60 0.00 (0.00%) As of 09/5/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock VNRX vs. RNAC, AVIR, NGNE, LFCR, ACB, CTNM, VOR, DBVT, MREO, and JBIOShould you be buying VolitionRx stock or one of its competitors? The main competitors of VolitionRx include Cartesian Therapeutics (RNAC), Atea Pharmaceuticals (AVIR), Neurogene (NGNE), Lifecore Biomedical (LFCR), Aurora Cannabis (ACB), Contineum Therapeutics (CTNM), Vor Biopharma (VOR), DBV Technologies (DBVT), Mereo BioPharma Group (MREO), and Jade Biosciences (JBIO). These companies are all part of the "pharmaceutical products" industry. VolitionRx vs. Its Competitors Cartesian Therapeutics Atea Pharmaceuticals Neurogene Lifecore Biomedical Aurora Cannabis Contineum Therapeutics Vor Biopharma DBV Technologies Mereo BioPharma Group Jade Biosciences Cartesian Therapeutics (NASDAQ:RNAC) and VolitionRx (NYSE:VNRX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk, dividends and media sentiment. Do analysts prefer RNAC or VNRX? Cartesian Therapeutics presently has a consensus price target of $40.00, suggesting a potential upside of 275.94%. VolitionRx has a consensus price target of $3.50, suggesting a potential upside of 481.40%. Given VolitionRx's stronger consensus rating and higher probable upside, analysts clearly believe VolitionRx is more favorable than Cartesian Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cartesian Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80VolitionRx 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has better earnings and valuation, RNAC or VNRX? VolitionRx has lower revenue, but higher earnings than Cartesian Therapeutics. VolitionRx is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCartesian Therapeutics$38.91M7.11-$77.42M-$52.83-0.20VolitionRx$1.32M49.10-$35.32M-$0.25-2.41 Does the media refer more to RNAC or VNRX? In the previous week, Cartesian Therapeutics had 2 more articles in the media than VolitionRx. MarketBeat recorded 2 mentions for Cartesian Therapeutics and 0 mentions for VolitionRx. Cartesian Therapeutics' average media sentiment score of 1.67 beat VolitionRx's score of 0.00 indicating that Cartesian Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Cartesian Therapeutics Very Positive VolitionRx Neutral Which has more risk & volatility, RNAC or VNRX? Cartesian Therapeutics has a beta of 0.39, indicating that its stock price is 61% less volatile than the S&P 500. Comparatively, VolitionRx has a beta of 1.27, indicating that its stock price is 27% more volatile than the S&P 500. Do insiders and institutionals hold more shares of RNAC or VNRX? 87.0% of Cartesian Therapeutics shares are held by institutional investors. Comparatively, 8.1% of VolitionRx shares are held by institutional investors. 60.3% of Cartesian Therapeutics shares are held by company insiders. Comparatively, 10.4% of VolitionRx shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Is RNAC or VNRX more profitable? Cartesian Therapeutics has a net margin of 0.00% compared to VolitionRx's net margin of -2,321.14%. Company Net Margins Return on Equity Return on Assets Cartesian TherapeuticsN/A N/A -6.36% VolitionRx -2,321.14%N/A -163.39% SummaryCartesian Therapeutics beats VolitionRx on 9 of the 16 factors compared between the two stocks. Get VolitionRx News Delivered to You Automatically Sign up to receive the latest news and ratings for VNRX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VNRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VNRX vs. The Competition Export to ExcelMetricVolitionRxDiagnostic substances IndustryMedical SectorNYSE ExchangeMarket Cap$64.77M$21.85M$5.82B$21.33BDividend YieldN/AN/A6.71%3.50%P/E Ratio-1.67N/A76.0829.63Price / Sales49.1018.48466.0148.71Price / CashN/AN/A36.9624.54Price / Book-5.47N/A11.454.55Net Income-$35.32M-$19.12M$3.29B$999.70M7 Day Performance-12.75%-12.75%1.23%0.58%1 Month Performance-9.88%-9.88%7.89%5.66%1 Year Performance-13.74%-13.74%62.81%17.40% VolitionRx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VNRXVolitionRx2.0311 of 5 stars$0.60-5.2%$3.50+481.4%-16.0%$64.77M$1.32M-1.6780RNACCartesian Therapeutics2.2149 of 5 stars$11.25+0.2%$40.00+255.6%-24.2%$292M$38.91M-0.2164News CoveragePositive NewsAVIRAtea Pharmaceuticals2.3255 of 5 stars$3.66flat$6.00+63.9%-6.9%$290.45MN/A-2.2770NGNENeurogene2.4093 of 5 stars$19.98-0.1%$46.17+131.1%-42.0%$285.30M$930K-4.6490News CoveragePositive NewsLFCRLifecore Biomedical1.1333 of 5 stars$7.59-0.1%$8.00+5.4%+64.4%$284.30M$128.87M-5.79690Trending NewsAnalyst ForecastAnalyst RevisionACBAurora Cannabis0.0896 of 5 stars$5.23+4.8%N/A-12.3%$281.70M$246.72M-27.531,130CTNMContineum Therapeutics2.7096 of 5 stars$10.39+4.5%$22.75+119.0%-35.2%$278.74M$50M-4.7231News CoverageShort Interest ↑VORVor Biopharma0.5046 of 5 stars$2.06-5.1%N/AN/A$274.90MN/A-0.15140DBVTDBV Technologies2.8718 of 5 stars$9.79-2.1%$14.75+50.7%+125.5%$273.90M$4.15M-2.0580News CoverageGap DownMREOMereo BioPharma Group2.5864 of 5 stars$1.74+2.4%$7.40+325.3%-60.0%$270.30M$10M-24.8640Positive NewsJBIOJade Biosciences2.9542 of 5 stars$7.90-4.0%$16.00+102.5%N/A$268.52MN/A-0.2620 Related Companies and Tools Related Companies RNAC Alternatives AVIR Alternatives NGNE Alternatives LFCR Alternatives ACB Alternatives CTNM Alternatives VOR Alternatives DBVT Alternatives MREO Alternatives JBIO Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:VNRX) was last updated on 9/6/2025 by MarketBeat.com Staff From Our PartnersWarren Buffett's Strangest AI InvestmentTrump Schedules Controversial 'Market Reset' for September 30 Behind closed doors, the White House has orde...Altimetry | SponsoredMusk Warns. Trump Acts. Your Retirement May Depend on ItWith Donald Trump back in the White House, many believe an economic revival could be underway — but it also br...American Alternative | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredREVEALED: Something Big Happening Behind White House Doorswhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredTrump’s national nightmare is hereWashington just added $1 trillion to the national debt in less than two months — an astonishing pace of spendi...Porter & Company | SponsoredOdd trade could help investors secure their wealth in 2025The most profitable phrase you’ve never heard of... Have you heard of 310F? This simple string of code coul...Eagle Publishing | SponsoredWall Street Legend Issues Urgent AI Stock Warning'Hidden AI' is taking the U.S. stock market by storm.Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VolitionRx Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share VolitionRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
